Understanding and targeting features of Myc-driven Osteosarcoma
Official title: Modeling and targeting intrinsic and extrinsic features of Myc-driven Osteosarcoma
Funded at Emory University · NIH-11049430 · Data updated 2026-11-12
This study is looking at how certain genetic changes in Myc-driven osteosarcoma, a type of bone cancer that often affects kids, can impact how the tumor grows and responds to treatment, with the hope of finding better ways to help patients fight this tough disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | March 1, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $452,549 |
| NIH project number | 1R01CA288967-01A1 |
| Project ID | NIH-11049430 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are pediatric patients diagnosed with osteosarcoma, particularly those with amplification of chromosome 8q24.
✕Less likely to help
Patients with osteosarcoma who do not have the Myc amplification or those with other types of bone tumors may not benefit from this research.
What this research studies
This research investigates the unique characteristics of Myc-driven osteosarcoma, a common bone tumor in children, particularly focusing on the genetic alterations associated with this cancer. The study aims to identify how these genetic changes affect the tumor's behavior and its interaction with the surrounding environment, which may influence treatment outcomes. By analyzing data from various sources and using advanced biological models, the research seeks to uncover potential therapeutic targets that could lead to more effective treatments for patients with this aggressive form of cancer.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted therapies that improve survival rates and reduce relapse in patients with Myc-amplified osteosarcoma.
How similar studies have gone: Previous research has shown promise in targeting oncogenes like Myc in other cancers, suggesting potential for success in this novel approach for osteosarcoma.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Yustein, Jason — Emory University
- Study coordinator: Yustein, Jason
Related research
Other NIH-funded projects on the same topics.
-
Understanding how bone cancer cells rely on certain pathways to grow in childhood osteosarcoma
This grant studies how specific cancer-related pathways in bone-forming cells drive osteosarcoma in children, with the aim of finding better treatments.
-
Histotripsy + immune boost to fight osteosarcoma
A new treatment idea combines a precise non-surgical ultrasound method with an immune-boosting compound to help fight bone cancer in people and dogs.
-
Genomically guided drug testing for osteosarcoma in patient-derived models
A precision approach tests new drugs on osteosarcoma models created from patients to find promising treatments for kids and teens.
-
New ways to stop osteosarcoma from spreading
Researchers are testing new approaches to block how osteosarcoma spreads, with the aim of improving survival for children and adults with metastatic disease.
-
Targeting OST Redundancy to Treat Osteosarcoma
A study in people with advanced bone cancer to see if new OST-targeting drugs can slow or stop tumor growth.
-
Focal Adhesion Kinase inhibitor to block osteosarcoma spread to the lungs
A cancer treatment plan tests whether blocking a specific cell signal can stop osteosarcoma from growing and spreading to the lungs in kids and young people.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.